Heart risk in hypoparathyroidism: could a Once-Daily injection protect arteries?
NCT ID NCT07707479
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study investigates whether long-acting parathyroid hormone (PTH) analogues can reduce signs of early heart and blood vessel damage in adults with chronic hypoparathyroidism. Researchers will compare artery stiffness and heart function in people taking the PTH analogue palopegteriparatide, those on standard therapy, and healthy volunteers. Participants will be followed for 12 months with vascular tests, heart imaging, and blood work to track changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a long-acting parathyroid hormone (PTH) analogue called palopegteriparatide (TransCon PTH)
- What this could lead to
- If successful, this could show that PTH analogues protect the heart and arteries in people with hypoparathyroidism, potentially reducing their risk of cardiovascular disease.
- What could go wrong
- This is an observational follow-up study, not a randomized trial, so results may be influenced by other factors. The treatment is already approved, but its heart benefits are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexandra General Hospital of Athens
Athens, 11527, Greece
-
Medical School, National and Kapodistrian University of Athens, LAIKO General Hospital of Athens
Athens, 11527, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.